VolitionRx Limited Announces Closing of Underwritten Public Offering of $6.9 Million Common Shares

HENDERSON, Nev., August 2, 2022 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multinational epigenetics company, today announced the closing of its previously announced underwritten public offering of 3,450,000 common shares, including the full exercise of the underwriter’s over-allotment option, at a public offering price of $2.00 per share. Gross proceeds to Volition of the offering were $6.9 million, before deducting underwriting commissions and other estimated offering costs payable by Volition. All Common Shares sold under the Offer were tendered by Volition.

Volition intends to use the net proceeds of the offering for research and ongoing product development, clinical studies, product commercialization, working capital and other general corporate purposes, including including potential strategic acquisitions.

Newbridge Securities Corporation acted as sole bookrunner for the offering.

The securities were issued by Volition pursuant to a “pending” registration statement on Form S-3 (File No. 333-259783) previously filed with the Securities and Exchange Commission (the “SEC”) on September 24, 2021 and declared effective by with the SEC on November 8, 2021. A definitive prospectus supplement and related base prospectus relating to the offering were filed with the SEC on August 1, 2022 and are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and accompanying base prospectus relating to the offering may also be obtained from Newbridge Securities Corporation, Attn: Equity Syndicate Department, 1200 North Federal Highway, Suite 400, Boca RatonFL 33432, by email to [email protected], or by phone at (877) 447-9625.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, and there will be no sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Will

Volition is a multinational epigenetics company that applies its Nucleosomics™ platform across its subsidiaries to develop simple, easy-to-use and cost-effective blood tests to help diagnose and monitor a range of life-changing diseases, including certain cancers and diseases. associated with NETosis such as sepsis and COVID-19. Early diagnosis and follow-up have the potential not only to prolong patients’ lives, but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluids, an indication that disease is present. Volition primarily focuses on human diagnostics and monitoring, but also has a subsidiary focused on animal diagnostics and monitoring.

Volition’s research and development activities are centered on Belgiumwith an innovation lab and office in the United States and additional offices in London and Singapore.

Media
Louise Batchelor/Debra DaglichWill
[email protected]
+44 (0)7557 774620

Investors
Scott PowellWill
[email protected]
+1 (646) 650 1351

Joseph GreenEdison Advisors
[email protected]
+1 (646) 653 7030

Caution Regarding Forward-Looking Statements

Statements contained in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which relate to matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements reflect management’s current beliefs and expectations and include statements regarding the public offering, including the intended use of the offering proceeds. All statements other than statements of historical fact are statements that could be considered forward-looking statements. Although Volition believes that the expectations reflected in these forward-looking statements are reasonable, it cannot guarantee that these expectations will prove to be correct. Forward-looking statements are subject to risks and uncertainties that may cause Volition’s actual operations or results to differ materially from those indicated or implied by any forward-looking statement, including, without limitation, due to risks and uncertainties relating to market conditions and the satisfaction of closing conditions relating to the proposed public offering, the risks disclosed in the section entitled “Risk Factors” included in the final prospectus supplement filed with the SEC on August 2022, and risks disclosed in other documents Volition files from time to time with the SEC, including Volition’s Quarterly Reports on Form 10-Q and its Annual Report on Form 10-K. Forward-looking statements are made as of the date of this release and, except as required by law, Volition does not undertake to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its affiliates.

SOURCE VolitionRx Limited

Comments are closed.